AU2017259275C1 - Compositions and methods related to HIV-1 immunogens - Google Patents

Compositions and methods related to HIV-1 immunogens Download PDF

Info

Publication number
AU2017259275C1
AU2017259275C1 AU2017259275A AU2017259275A AU2017259275C1 AU 2017259275 C1 AU2017259275 C1 AU 2017259275C1 AU 2017259275 A AU2017259275 A AU 2017259275A AU 2017259275 A AU2017259275 A AU 2017259275A AU 2017259275 C1 AU2017259275 C1 AU 2017259275C1
Authority
AU
Australia
Prior art keywords
asn
leu
ile
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017259275A
Other languages
English (en)
Other versions
AU2017259275A1 (en
AU2017259275B2 (en
Inventor
Dennis Burton
Natalia DE VAL
Linling HE
Leopold KONG
Andrew B. WARD
Ian A. Wilson
Jiang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2017259275A1 publication Critical patent/AU2017259275A1/en
Application granted granted Critical
Publication of AU2017259275B2 publication Critical patent/AU2017259275B2/en
Priority to AU2021221582A priority Critical patent/AU2021221582B2/en
Publication of AU2017259275C1 publication Critical patent/AU2017259275C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017259275A 2016-05-02 2017-05-01 Compositions and methods related to HIV-1 immunogens Active AU2017259275C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021221582A AU2021221582B2 (en) 2016-05-02 2021-08-25 Compositions and methods related to HIV-1 immunogens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330604P 2016-05-02 2016-05-02
US62/330,604 2016-05-02
PCT/US2017/030375 WO2017192434A1 (en) 2016-05-02 2017-05-01 Compositions and methods related to hiv-1 immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021221582A Division AU2021221582B2 (en) 2016-05-02 2021-08-25 Compositions and methods related to HIV-1 immunogens

Publications (3)

Publication Number Publication Date
AU2017259275A1 AU2017259275A1 (en) 2018-11-15
AU2017259275B2 AU2017259275B2 (en) 2021-06-24
AU2017259275C1 true AU2017259275C1 (en) 2022-01-27

Family

ID=60203504

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017259275A Active AU2017259275C1 (en) 2016-05-02 2017-05-01 Compositions and methods related to HIV-1 immunogens
AU2021221582A Active AU2021221582B2 (en) 2016-05-02 2021-08-25 Compositions and methods related to HIV-1 immunogens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021221582A Active AU2021221582B2 (en) 2016-05-02 2021-08-25 Compositions and methods related to HIV-1 immunogens

Country Status (13)

Country Link
US (5) US10647748B2 (enExample)
EP (1) EP3452494A4 (enExample)
JP (1) JP7046832B2 (enExample)
CN (1) CN109153704A (enExample)
AU (2) AU2017259275C1 (enExample)
BR (1) BR112018072248A2 (enExample)
CA (1) CA3022826A1 (enExample)
EA (1) EA201892233A1 (enExample)
IL (2) IL299962A (enExample)
MX (1) MX2018013455A (enExample)
SG (1) SG11201809387QA (enExample)
WO (1) WO2017192434A1 (enExample)
ZA (1) ZA201807216B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241483A1 (en) * 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US20220041650A1 (en) * 2018-12-03 2022-02-10 Duke University Purification method for recombinant proteins and nanoparticles
WO2021021603A2 (en) * 2019-07-26 2021-02-04 The Scripps Research Institute Engineered hcv e2 immunogens and related vaccine compositions
AU2020381082B2 (en) * 2019-11-07 2022-09-22 Janssen Vaccines & Prevention B.V. Protein purification
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
EP4245767A4 (en) * 2020-11-12 2025-04-30 Xiamen University MODIFIED HUMAN IMMUNODEFICIENCY VIRUS MEMBRANE PROTEIN AND USE THEREOF
CN116769053B (zh) * 2023-05-26 2023-12-15 华中农业大学 重组AaLS-BPP融合肽、制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20140212458A1 (en) * 2012-11-05 2014-07-31 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP2011502521A (ja) 2007-11-12 2011-01-27 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
RU2540871C2 (ru) 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
CN105263506B (zh) 2013-01-07 2018-03-09 贝丝以色列女执事医疗中心 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
SG10202001956UA (en) * 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20140212458A1 (en) * 2012-11-05 2014-07-31 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEORGIEV et al., "Single-Chain Soluble BG 505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env", J Virol., (2015-05), vol. 89, no. 10 *
KWINTEN SLIEPEN ET AL, "Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity", RETROVIROLOGY, (2015-09-26), vol. 11, no. 1, doi:10.1186/s12977-015-0210-4, page e1004767 *

Also Published As

Publication number Publication date
AU2017259275A1 (en) 2018-11-15
CA3022826A1 (en) 2017-11-09
US20200165303A1 (en) 2020-05-28
US11767347B2 (en) 2023-09-26
US20240083954A1 (en) 2024-03-14
EP3452494A1 (en) 2019-03-13
AU2021221582B2 (en) 2022-10-20
AU2017259275B2 (en) 2021-06-24
MX2018013455A (es) 2019-02-28
US20190048043A1 (en) 2019-02-14
IL299962A (en) 2023-03-01
CN109153704A (zh) 2019-01-04
WO2017192434A1 (en) 2017-11-09
JP7046832B2 (ja) 2022-04-04
JP2019522626A (ja) 2019-08-15
ZA201807216B (en) 2020-01-29
US11236134B2 (en) 2022-02-01
SG11201809387QA (en) 2018-11-29
IL262582B2 (en) 2023-06-01
AU2021221582A1 (en) 2021-10-07
US20220098244A1 (en) 2022-03-31
US10647748B2 (en) 2020-05-12
BR112018072248A2 (pt) 2019-02-12
US20250122247A1 (en) 2025-04-17
EP3452494A4 (en) 2020-01-01
EA201892233A1 (ru) 2019-07-31
IL262582A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
AU2021221582B2 (en) Compositions and methods related to HIV-1 immunogens
WO2016037154A1 (en) Recombinant hiv-1 envelope proteins and their use
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
JP5946766B2 (ja) Ｈｉｖワクチン組成物における使用又は診断手段としての使用のためのｈｉｖ関連ペプチドの組合せ又は融合物
US20230338507A1 (en) Hiv-1 env fusion peptide immunogens and their use
US20170035877A1 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2019042950A1 (en) IMPROVED HIV ENVELOPE GLYCOPROTETIC IMMUNOGENS
US20250059238A1 (en) Recombinant hiv env polypeptides and their uses
US10870683B2 (en) N-glycan deleted HIV-1 envelope glycoprotein trimers
EA050067B1 (ru) ПОЛИНУКЛЕОТИД, КОДИРУЮЩИЙ МОНОМЕР МОДИФИЦИРОВАННОГО ТРИМЕРНОГО БЕЛКА gp140 ОБОЛОЧКИ ВИЧ-1, СОДЕРЖАЩИЕ ЕГО ВЕКТОР И КЛЕТКА И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ ВИЧ-1
EA041182B1 (ru) Композиции и способы, связанные с иммуногенами вич-1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 OCT 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 OCT 2021